Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Aspirin  COVID-19 treatment studies for Aspirin  C19 studies: Aspirin  Aspirin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality, day 60 3% Improvement Relative Risk Mortality, day 30 2% c19early.org/e Campbell et al. Aspirin for COVID-19 Prophylaxis Is prophylaxis with aspirin beneficial for COVID-19? Retrospective 20,730 patients in the USA (March - December 2020) No significant difference in mortality Campbell et al., PLOS ONE, doi:10.1371/journal.pone.0267462 Favors aspirin Favors control
Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) or acetaminophen and relationship with mortality among United States Veterans after testing positive for COVID-19
Campbell et al., PLOS ONE, doi:10.1371/journal.pone.0267462
Campbell et al., Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) or acetaminophen and relationship with mortality.., PLOS ONE, doi:10.1371/journal.pone.0267462
May 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 28,856 COVID-19 patients in the USA, showing no significant difference in mortality for chronic aspirin use vs. sporadic NSAID use. Since aspirin is available OTC and authors only tracked prescriptions, many patients classified as sporadic users may have been chronic users.
risk of death, 3.0% lower, OR 0.97, p = 0.06, treatment 419, control 20,311, adjusted per study, propensity score weighting, multivariable, day 60, RR approximated with OR.
risk of death, 2.0% lower, OR 0.98, p = 0.10, treatment 419, control 20,311, adjusted per study, propensity score weighting, multivariable, day 30, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Campbell et al., 5 May 2022, retrospective, USA, peer-reviewed, 4 authors, study period 2 March, 2020 - 14 December, 2020.
Contact: heather.campbell@va.gov, virec@va.gov.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAspirinAll
Abstract: PLOS ONE RESEARCH ARTICLE Chronic use of non-steroidal antiinflammatory drugs (NSAIDs) or acetaminophen and relationship with mortality among United States Veterans after testing positive for COVID-19 a1111111111 a1111111111 a1111111111 a1111111111 a1111111111 OPEN ACCESS Citation: Campbell HM, Murata AE, Conner TA, Fotieo G (2022) Chronic use of non-steroidal antiinflammatory drugs (NSAIDs) or acetaminophen and relationship with mortality among United States Veterans after testing positive for COVID-19. PLoS ONE 17(5): e0267462. https://doi.org/ 10.1371/journal.pone.0267462 Editor: Chiara Lazzeri, Azienda Ospedaliero Universitaria Careggi, ITALY Received: May 19, 2021 Accepted: April 8, 2022 Published: May 5, 2022 Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication. Data Availability Statement: Data cannot be shared publicly because it involves sensitive human subject information. Data may be available for researchers who meet the criteria for access to confidential data after evaluation from affiliated IRB and VA Research and Development Committees. As a VA national legal policy (VHA Directive 1605.01), VA will only share patient data if there is a fully executed contractual agreement in place for the specific project. A common contractual mechanism utilized for this type of sharing is a Heather M. Campbell ID1☯*, Allison E. Murata1☯, Todd A. Conner1, Greg Fotieo2 1 Cooperative Studies Program, Clinical Research Pharmacy Coordinating Center, US Department of Veterans Affairs, Albuquerque, New Mexico, United States of America, 2 New Mexico VA Healthcare System, US Department of Veterans Affairs, Albuquerque, New Mexico, United States of America ☯ These authors contributed equally to this work. * heather.campbell@va.gov Abstract Non-steroidal anti-inflammatory drugs (NSAIDs) and acetaminophen are among the mostfrequently used medications. Although these medications have different mechanisms of action, they have similar indications and treatment duration has been positively correlated with cardiovascular risk although the degree of risk varies by medication. Our objective was to study treatment effects of chronic use of individual NSAID medications and acetaminophen on all-cause mortality among patients who tested positive for COVID-19 while accounting for adherence. We used the VA national datasets in this retrospective cohort study to differentiate between sporadic and chronic medication use: sporadic users filled an NSAID within the last year, but not recently or regularly. Using established and possible risk factors for severe COVID-19, we used propensity scores analysis to adjust for differences in baseline characteristics between treatment groups. Then, we used multivariate logistic regression incorporating inverse propensity score weighting to assess mortality. The cohort consisted of 28,856 patients. Chronic use of aspirin, ibuprofen, naproxen, meloxicam, celecoxib, diclofenac or acetaminophen was not associated with significant differences in mortality at 30 days (OR = 0.98, 95% CI: 0.95–1.00; OR = 0.99, 95% CI: 0.98–1.00; OR = 1.00, 95% CI: 0.98–1.01; OR = 0.99, 95% CI: 0.98–1.00; OR = 1.00, 95% CI: 0.98–1.01; OR = 0.99, 95% CI: 0.97–1.01; and OR = 1.00, 95% CI: 0.99–1.02, respectively) nor at 60..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit